Treatment of APL patients with all-trans retinoic acid (ATRA) or As2O3, reverses the disease phenotype and promotes PML-RARα degradation, which leads to PML NB reformation (Zhu et al., 1997, 1999). The gene discussed is PML; the disease is acute promyelocytic leukemia.